159 related articles for article (PubMed ID: 38501542)
1. Obesity correlates with the immunosuppressive ILC2s-MDSCs axis in advanced breast cancer.
Liu W; Li B; Liu D; Zhao B; Sun G; Ding J
Immun Inflamm Dis; 2024 Mar; 12(3):e1196. PubMed ID: 38501542
[TBL] [Abstract][Full Text] [Related]
2. Group 2 innate lymphoid cells promote TNBC lung metastasis via the IL-13-MDSC axis in a murine tumor model.
Zhao N; Zhu W; Wang J; Liu W; Kang L; Yu R; Liu B
Int Immunopharmacol; 2021 Oct; 99():107924. PubMed ID: 34217145
[TBL] [Abstract][Full Text] [Related]
3. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
Trabanelli S; Chevalier MF; Martinez-Usatorre A; Gomez-Cadena A; Salomé B; Lecciso M; Salvestrini V; Verdeil G; Racle J; Papayannidis C; Morita H; Pizzitola I; Grandclément C; Bohner P; Bruni E; Girotra M; Pallavi R; Falvo P; Leibundgut EO; Baerlocher GM; Carlo-Stella C; Taurino D; Santoro A; Spinelli O; Rambaldi A; Giarin E; Basso G; Tresoldi C; Ciceri F; Gfeller D; Akdis CA; Mazzarella L; Minucci S; Pelicci PG; Marcenaro E; McKenzie ANJ; Vanhecke D; Coukos G; Mavilio D; Curti A; Derré L; Jandus C
Nat Commun; 2017 Sep; 8(1):593. PubMed ID: 28928446
[TBL] [Abstract][Full Text] [Related]
4. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for
Jou E; Rodriguez-Rodriguez N; Ferreira AF; Jolin HE; Clark PA; Sawmynaden K; Ko M; Murphy JE; Mannion J; Ward C; Matthews DJ; Buczacki SJA; McKenzie ANJ
Sci Immunol; 2022 Jun; 7(72):eabn0175. PubMed ID: 35658010
[TBL] [Abstract][Full Text] [Related]
5. The clinical association of programmed death-1/PD-L1 axis, myeloid derived suppressor cells subsets and regulatory T cells in peripheral blood of stable COPD patients.
Zhang M; Wan Y; Han J; Li J; Gong H; Mu X
PeerJ; 2024; 12():e16988. PubMed ID: 38560459
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
[TBL] [Abstract][Full Text] [Related]
7. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.
Ruan WS; Feng MX; Xu J; Xu YG; Song CY; Lin LY; Li L; Lu YQ
Front Immunol; 2020; 11():1299. PubMed ID: 32719675
[No Abstract] [Full Text] [Related]
8. Peripheral expansion of myeloid-derived suppressor cells is related to disease activity and damage accrual in inflammatory myopathies.
Torres-Ruiz J; Absalón-Aguilar A; Reyes-Islas JA; Cassiano-Quezada F; Mejía-Domínguez NR; Pérez-Fragoso A; Maravillas-Montero JL; Núñez-Álvarez C; Juárez-Vega G; Culebro-Bermejo A; Gómez-Martín D
Rheumatology (Oxford); 2023 Feb; 62(2):775-784. PubMed ID: 35766810
[TBL] [Abstract][Full Text] [Related]
9. Possible Metastatic Stage-Dependent ILC2 Activation Induces Differential Functions of MDSCs through IL-13/IL-13Rα1 Signaling during the Progression of Breast Cancer Lung Metastasis.
Ito A; Akama Y; Satoh-Takayama N; Saito K; Kato T; Kawamoto E; Gaowa A; Park EJ; Takao M; Shimaoka M
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805039
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Kajihara N; Kobayashi T; Otsuka R; Nio-Kobayashi J; Oshino T; Takahashi M; Imanishi S; Hashimoto A; Wada H; Seino KI
Cancer Immunol Immunother; 2023 Apr; 72(4):851-864. PubMed ID: 36104597
[TBL] [Abstract][Full Text] [Related]
11. PD-1 Affects the Immunosuppressive Function of Group 2 Innate Lymphoid Cells in Human Non-Small Cell Lung Cancer.
Shen C; Liu C; Zhang Z; Ping Y; Shao J; Tian Y; Yu W; Qin G; Liu S; Wang L; Zhang Y
Front Immunol; 2021; 12():680055. PubMed ID: 34194433
[TBL] [Abstract][Full Text] [Related]
12. Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing.
Pal S; Dey D; Chakraborty BC; Nandi M; Khatun M; Banerjee S; Santra A; Ghosh R; Ahammed SM; Chowdhury A; Datta S
Hepatology; 2022 Sep; 76(3):759-774. PubMed ID: 35000202
[TBL] [Abstract][Full Text] [Related]
13. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
14. Enhanced circulating ILC2s and MDSCs may contribute to ensure maintenance of Th2 predominant in patients with lung cancer.
Wu Y; Yan Y; Su Z; Bie Q; Chen X; Barnie PA; Guo Q; Wang S; Xu H
Mol Med Rep; 2017 Jun; 15(6):4374-4381. PubMed ID: 28487978
[TBL] [Abstract][Full Text] [Related]
15. The IL-25/ILC2 axis promotes lung cancer with a concomitant accumulation of immune-suppressive cells in tumors in humans and mice.
Bahhar I; Eş Z; Köse O; Turna A; Günlüoğlu MZ; Çakır A; Duralı D; Magnusson FC
Front Immunol; 2023; 14():1244437. PubMed ID: 37781372
[TBL] [Abstract][Full Text] [Related]
16. Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus.
Park MJ; Baek JA; Choi JW; Jang SG; Kim DS; Park SH; Cho ML; Kwok SK
Front Immunol; 2021; 12():606024. PubMed ID: 33986739
[TBL] [Abstract][Full Text] [Related]
17. Decidua-derived granulocyte macrophage colony-stimulating factor induces polymorphonuclear myeloid-derived suppressor cells from circulating CD15+ neutrophils.
Li C; Chen C; Kang X; Zhang X; Sun S; Guo F; Wang Q; Kou X; Bai W; Zhao A
Hum Reprod; 2020 Dec; 35(12):2677-2691. PubMed ID: 33067638
[TBL] [Abstract][Full Text] [Related]
18. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
[TBL] [Abstract][Full Text] [Related]
19. A novel type-2 innate lymphoid cell-based immunotherapy for cancer.
Saranchova I; Xia CW; Besoiu S; Finkel PL; Ellis SLS; Kari S; Munro L; Pfeifer CG; Fazli L; Gleave ME; Jefferies WA
Front Immunol; 2024; 15():1317522. PubMed ID: 38524132
[TBL] [Abstract][Full Text] [Related]
20. Neuronal-Activated ILC2s Promote IL-17A Production in Lung γδ T Cells During Sepsis.
Chen W; Lai D; Li Y; Wang X; Pan Y; Fang X; Fan J; Shu Q
Front Immunol; 2021; 12():670676. PubMed ID: 33995408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
